Details of the Drug Reposition

General Information of This Drug (ID: DMMHR1U)

Drug Name
Denileukin diftitox   DMMHR1U
Therapeutic Class
Anticancer Agents

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
4 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Primary cutaneous T-cell lymphoma DIS35WVW N.A. Approved [1]
leukaemia DISS7D1V 2A60-2B33 Approved [2]
Plasma cell myeloma DIS0DFZ0 2A83.1 Approved [3]
Epithelial ovarian cancer DIS56MH2 2B5D Approved [3]
------------------------------------------------------------------------------------
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Non-small-cell lung cancer DIS5Y6R9 2C25.Y Phase 2 [2]
------------------------------------------------------------------------------------
1 Discontinued in Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Fallopian tube carcinoma DIST7A80 N.A. Discontinued in Phase 3 [4]
------------------------------------------------------------------------------------

References

1 Advanced-stage primary cutaneous T-cell lymphoma treated with bexarotene and denileukin diftitox. Case Rep Dermatol. 2011 Jan;3(1):13-7.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7044).
3 A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
4 ClinicalTrials.gov (NCT00865280) Study the Safety and Efficacy of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI). U.S. National Institutes of Health.